Halofuginone

Halofuginone

Cat#
ALK-0062
Product Name
Halofuginone
CAS No.
55837-20-2
Synonyms
RU-19110
Description
Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM. Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity. Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects.
Structural Formula
Halofuginone
MW
414.68
MF
C16H17BrClN3O3
Purity
0.9978
Appearance
Solid
Solubility
DMSO : 20 mg/mL(48.23 mM;ultrasonic and adjust pH to 5 with HCl)
Source
Plants >Saxifragaceae > Dichroa febrifugaLour
Storage
-20℃ for 3 years
IC50 & Target
Amebae Plasmodium
Shipping
Room temperature in continental US; may vary elsewhere.
SMILES
O=C1N(CC(C[C@@H]2NCCC[C@H]2O)=O)C=NC3=C1C=C(Cl)C(Br)=C3
In Vivo
Halofuginone attenuates progression of OA in anterior cruciate ligament transection (ACLT) mice. Lower concentration has minimal effects on subchondral bone and higher concentration (2.5 mg/kg) induces proteoglycan loss in articular cartilage. Halofuginone decreases NRF2 protein levels in tumors.
In Vitro
Halofuginone competitively inhibits prolyl-tRNA synthetase by occupying both the prolineand tRNA-binding pockets of prolyl-tRNA synthetase. The IC50s of Halofuginone (1, 10, 100, 1000, 10000 nM; 48 hours) are 114.6 and 58.9 nM in KYSE70 and A549 cells, respectively. The IC50s of Halofuginone (1, 10, 100, 1000 nM; 24 hours) for NRF2 protein are 22.3 and 37.2 nM in KYSE70 and A549 cells, respectively. The IC50 of Halofuginone for global protein synthesis is 22.6 and 45.7 nM in KYSE70 and A549 cells, respectively. Halofuginone increases voltage-gated K+ (Kv) currents in pulmonary artery smooth muscle cells (PASMC) and K+ currents through KCNA5 channels in HEK cells transfected with KCNA5 gene. Halofuginone (0.03-1μM) inhibits receptor-operated Ca2+ entry (ROCE) in HEK cells transfected with calcium-sensing receptor gene and attenuates store-operated Ca2+ entry (SOCE) in PASMC.
Our products/services are For Research Use Only. Not For Clinical Use!
Online Inquiry
0
Inquiry Basket